Cohance Lifesciences Ltd

Cohance Life Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Cohance Lifesciences Ltd

₹ 1,027 -2.62%
09 Jun 10:47 a.m.
suvenpharm.com BSE: 543064 NSE: COHANCE
About

Hyderabad based CDMO company that offers services to leading global pharmaceutical and fine chemical majors in their NCE development endeavours. From process research & development to late-stage clinical and commercial manufacturing we are committed to provide customers with products fulfilling customer needs and expectations.[1]

Key Points

Market Position
The company has established a strong presence in the contract research and manufacturing services (CRAMS) sector and is one of the top 5 providers of high-end intermediates to innovators in India. [1]

Website BSE NSE
  • Market Cap ₹ 26,146 Cr.
  • Current Price ₹ 1,027
  • High / Low ₹ 1,360 / 638
  • Stock P/E 98.7
  • Book Value ₹ 66.6
  • Dividend Yield 0.00 %
  • ROCE 16.8 %
  • ROE 14.1 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Promoter holding has increased by 16.3% over last quarter.

Cons

  • Stock is trading at 15.8 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of 7.51% over past five years.
  • Debtor days have increased from 54.4 to 86.7 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 BSE SmallCap Nifty MNC

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
364 339 278 354 369 348 231 220 253 231 258 307 402
207 188 179 207 198 181 133 154 180 151 154 189 328
Operating Profit 157 151 100 147 172 167 98 66 73 80 104 118 74
OPM % 43% 45% 36% 41% 47% 48% 42% 30% 29% 35% 40% 38% 18%
17 11 11 13 11 11 20 14 17 18 14 16 11
Interest 2 1 0 1 5 1 0 2 2 2 2 3 6
Depreciation 10 12 12 12 12 13 12 13 17 13 17 20 27
Profit before tax 161 149 98 146 166 164 105 65 71 83 100 110 52
Tax % 43% 28% 27% 26% 25% 26% 25% 29% 25% 27% 18% 24% 25%
92 108 72 108 124 121 80 47 53 61 82 83 39
EPS in Rs 3.60 4.22 2.83 4.23 4.87 4.74 3.13 1.84 2.10 2.39 3.23 3.26 1.65
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
378 834 1,010 1,320 1,340 1,051 1,198
206 449 567 738 766 645 822
Operating Profit 172 385 443 582 574 406 375
OPM % 45% 46% 44% 44% 43% 39% 31%
1 66 68 133 46 62 59
Interest 3 23 12 9 13 7 12
Depreciation 12 24 32 39 48 55 77
Profit before tax 158 405 468 668 560 406 344
Tax % 31% 22% 23% 32% 27% 26% 23%
109 317 362 454 411 300 265
EPS in Rs 5,463.50 12.45 14.23 17.83 16.16 11.80 10.52
Dividend Payout % 0% 20% 14% 28% 37% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 8%
3 Years: -3%
TTM: 14%
Compounded Profit Growth
10 Years: %
5 Years: -3%
3 Years: -13%
TTM: -1%
Stock Price CAGR
10 Years: %
5 Years: 46%
3 Years: 30%
1 Year: 63%
Return on Equity
10 Years: %
5 Years: 22%
3 Years: 17%
Last Year: 14%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 0.00 13 25 25 25 25 25
Reserves 578 832 1,155 1,502 1,710 2,025 1,671
83 186 143 97 70 65 279
123 142 151 205 160 138 1,056
Total Liabilities 783 1,173 1,474 1,830 1,966 2,254 3,032
271 357 441 534 663 670 1,714
CWIP 111 102 96 30 165 179 255
Investments 7 338 542 598 536 904 337
394 376 395 667 601 501 726
Total Assets 783 1,173 1,474 1,830 1,966 2,254 3,032

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
50 407 383 330 457 358 288
-65 -413 -311 -136 -195 -362 -255
26 7 -76 -156 -242 -14 3
Net Cash Flow 11 1 -5 37 20 -18 36

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 142 51 37 65 30 46 87
Inventory Days 556 278 243 259 279 268 199
Days Payable 190 113 100 97 63 49 96
Cash Conversion Cycle 509 217 180 228 247 265 190
Working Capital Days 285 105 95 126 117 130 153
ROCE % 50% 40% 41% 32% 19% 17%

Shareholding Pattern

Numbers in percentages

3 Recently
Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025May 2025
60.00% 60.00% 60.00% 60.00% 60.00% 60.00% 50.10% 50.10% 50.10% 50.10% 50.10% 66.41%
7.58% 8.11% 9.47% 9.50% 10.01% 10.14% 9.54% 9.80% 10.70% 10.84% 11.05% 7.38%
10.87% 11.36% 11.43% 10.63% 14.13% 15.94% 17.24% 17.42% 16.95% 16.67% 16.60% 11.02%
0.00% 0.00% 0.00% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01% 0.01%
21.56% 20.55% 19.10% 19.88% 15.85% 13.93% 23.11% 22.67% 22.26% 22.37% 22.24% 15.18%
No. of Shareholders 82,57779,41272,88572,16773,71570,05268,93265,77769,33784,21086,32588,658

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls